Special Interview with Dr. Randi J. Hagerman
On April 26, 2024, the Editorial Office of Rare Disease and Orphan Drugs Journal was delighted to interview Dr. Randi J. Hagerman, a distinguished specialist in Fragile X Syndrome, regarding her article titled "Molecular mechanisms for targeted treatments in fragile X syndrome". During the interview, Dr. Hagerman elaborated on the key points of her article, current research, and prospects within the field of Fragile X Syndrome, and offered suggestions for the future development of the journal. Let us delve into the insights shared by Dr. Hagerman during this enlightening video interview.
Author Biography
Dr. Randi J. Hagerman is a prominent American physician serving as the medical director of the MIND Institute at the University of California, Davis. She works for the Pediatrics Department under the Division of Child Development and Behavior. Dr. Hagerman holds international recognition for her research in the genetics of autism spectrum disorder, particularly focusing on genomic instability. Together with her husband, Paul Hagerman, she identified Fragile X-associated tremor/ataxia syndrome (FXTAS), a neurological disorder affecting older male and rare female carriers of fragile X. Dr. Hagerman boasts an extensive publication record, with over 200 peer-reviewed articles and book chapters on neurodevelopmental disorders. Her research interests span various topics, including repeat expansion and the genetics of neurodevelopmental disorders (e.g., Fragile-X). Furthermore, she contributes to the Editorial Boards of esteemed publications, including Journal of Developmental and Behavioral Pediatrics and Molecular Autism.
The interview questions are outlined below:
1) Could you please provide a brief overview of the main content covered in your article “Molecular mechanisms for targeted treatments in fragile X syndrome” for our audience?
2) What do you consider the most significant highlight of this article?
3) How do you envision this article contributing to the future advancement of Fragile X Syndrome research?
4) Given your expertise in Autism Spectrum Disorder research, could you share any recent progress and your predictions for the future development of this field?
5) Leveraging your rich experience, could you offer some valuable suggestions for Rare Disease and Orphan Drugs Journal regarding subject research and other pertinent aspects?
Editor: Cyndi Guan
Language Editor: Catherine Yang
Production Editor: Yan Zhang
Respectfully Submitted by the Journal Editorial Office
Rare Disease and Orphan Drugs Journal
